A cytokine-centric view of the pathogenesis and treatment of autoimmune arthritis

Journal of Interferon and Cytokine Research

Volumn 31, Issue 12, 2011, Pages 927-940

  Astry, Brian ^a   Harberts, Erin ^a   Moudgil, Kamal D ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 27; INTERLEUKIN 32; INTERLEUKIN 33; INTERLEUKIN 35;

AUTOIMMUNE DISEASE; DISEASE ASSOCIATION; HUMAN; INFLAMMATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; TH1 CELL; TH2 CELL;

ANIMALS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; CYTOKINES; HUMANS; INTERLEUKIN-17; INTERLEUKIN-23; JOINTS; LYMPHOID TISSUE; SIGNAL TRANSDUCTION;

EID: 83455169460     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2011.0094     Document Type: Review

References (175)

1. Abbas AK, Murphy KM, Sher A. 1996. Functional diversity of helper T lymphocytes. Nature 383(6603):787-93. (Pubitemid 26372655)
2. Adamopoulos IE, Chao CC, Geissler R, Laface D, Blumenschein W, Iwakura Y, et al. 2010. Interleukin-17A upregulates receptor activator of NF-kappaB on osteoclast precursors. Arthritis Res Ther 12(1):R29.
3. Agarwal S, Misra R, Aggarwal A. 2008. Interleukin 17 levels are increased in juvenile idiopathic arthritis synovial fluid and induce synovial fibroblasts to produce proinflammatory cy-tokines and matrix metalloproteinases. J Rheumatol 35(3):515-519. (Pubitemid 351374430)
4. Albanesi C, Scarponi C, Cavani A, Federici M, Nasorri F, Gir-olomoni G. 2000. Interleukin-17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-gamma-and in-terleukin-4-induced activation of human keratinocytes. J Invest Dermatol 115(1):81-87. (Pubitemid 30470196)
5. Alsaleh G, Sparsa L, Chatelus E, Ehlinger M, Gottenberg JE, Wachsmann D, Sibilia J. 2010. Innate immunity triggers IL-32 expression by fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Res Ther 12:R135.
6. Alves-Filho JC, Sonego F, Souto FO, Freitas A, Verri WA Jr., Auxiliadora-Martins M, et al. 2010. Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nat Med 16(6):708-712.
7. Amin MA, Rabquer BJ, Mansfield PJ, Ruth JH, Marotte H, Haas CS, et al. 2010. Interleukin 18 induces angiogenesis in vitro and in vivo via Src and Jnk kinases. Ann Rheum Dis 69(12): 2204-2212.
8. Andersson A, Kokkola R, Wefer J, Erlandsson-Harris H, Harris RA. 2004. Differential macrophage expression of IL-12 and IL-23 upon innate immune activation defines rat autoimmune susceptibility. J Leukoc Biol 76(6):1118-1124. (Pubitemid 39602947)
9. Awasthi A, Carrier Y, Peron JP, Bettelli E, Kamanaka M, Flavell RA, et al. 2007. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol 8(12):1380-1389. (Pubitemid 350131175)
10. Banda NK, Vondracek A, Kraus D, Dinarello CA, Kim SH, Bendele A, et al. 2003. Mechanisms of inhibition of collagen-induced arthritis by murine IL-18 binding protein. J Immunol 170(4):2100-2105. (Pubitemid 36197432)
11. Baslund B, Tvede N, Danneskiold-Samsoe B, Larsson P, Panayi G, Petersen J, et al. 2005. Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum 52(9):2686-2692. (Pubitemid 41369096)
12. Batten M, Li J, Yi S, Kljavin NM, Danilenko DM, Lucas S, Lee J, et al. 2006. Interleukin 27 limits autoimmune encephalomy-elitis by suppressing the development of interleukin 17-pro-ducing T cells. Nat Immunol 7:929-936. (Pubitemid 44263906)
13. Bessis N, Boissier MC. 2001. Novel pro-inflammatory interleu-kins: potential therapeutic targets in rheumatoid arthritis. Joint Bone Spine 68(6):477-481. (Pubitemid 34037276)
14. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. 2006. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441(7090):235-238.
15. Bingham CO 3rd. 2002. The pathogenesis of rheumatoid arthritis: pivotal cytokines involved in bone degradation and inflammation. J Rheumatol Suppl 65:3-9.
16. Brahn E. 1991. Animal models of rheumatoid arthritis. Clues to etiology and treatment. Clin Orthop Relat Res (265):42-53.
17. Brennan FM, McInnes IB. 2008. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 118(11):3537-3545.
18. Bush KA, Farmer KM, Walker JS, Kirkham BW. 2002. Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum 46(3):802-805. (Pubitemid 34214263)
19. Bush KA, Walker JS, Lee CS, Kirkham BW. 2001. Cytokine expression and synovial pathology in the initiation and spontaneous resolution phases of adjuvant arthritis: interleukin-17 expression is upregulated in early disease. Clin Exp Immunol 123(3):487-495. (Pubitemid 32289970)
20. Cagnard N, Letourneur F, Essabbani A, Devauchelle V, Mistou S, Rapinat A, et al. 2005. Interleukin-32, CCL2, PF4F1 and GFD10 are the only cytokine/chemokine genes differentially expressed by in vitro cultured rheumatoid and osteoarthritis fibroblast-like synoviocytes. Eur Cytokine Netw 16(4):289-292. (Pubitemid 350056544)
21. Cao Y, Doodes PD, Glant TT, Finnegan A. 2008. IL-27 induces a Th1 immune response and susceptibility to experimental arthritis. J Immunol 180(2):922-930.
22. Carroll HP, Paunovic V, Gadina M. 2008. Signalling, inflammation and arthritis: crossed signals: the role of interleukin-15 and-18 in autoimmunity. Rheumatology (Oxford) 47(9): 1269-1277.
23. Chaturvedi V, Collison LW, Guy CS, Workman CJ, Vignali DA. 2011. Cutting edge: human regulatory T cells require IL-35 to mediate suppression and infectious tolerance. J Immunol 186(12): 6661-6666.
24. Chen B, Hu J, Liao L, Sun Z, Han Q, Song Z, Zhao RC. 2010. Flk-1 + mesenchymal stem cells aggravate collagen-induced arthritis by up-regulating interleukin-6. Clin Exp Immunol 159(3):292-302.
25. Cho ML, Kang JW, Moon YM, Nam HJ, Jhun JY, Heo SB, et al. 2006. STAT3 and NF-kappaB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice. J Immunol 176(9):5652-5661.
26. Chtanova T, Tangye SG, Newton R, Frank N, Hodge MR, Rolph MS, Mackay CR. 2004. T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1/Th2 effector cells that provide help for B cells. J Immunol 173(1):68-78. (Pubitemid 38797327)
27. Chu CQ, Swart D, Alcorn D, Tocker J, Elkon KB. 2007. Inter-feron-gamma regulates susceptibility to collagen-induced arthritis through suppression of interleukin-17. Arthritis Rheum 56(4):1145-1151. (Pubitemid 46608639)
28. Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Bankoti J, et al. 2010. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol 11(12):1093-1101.
29. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, et al. 2007. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450(7169):566-569. (Pubitemid 350190247)
30. Dahl CA, Schall RP, He HL, Cairns JS. 1992. Identification of a novel gene expressed in activated natural killer cells and T cells. J Immunol 148(2):597-603.
31. Devergne O, Birkenbach M, Kieff E. 1997. Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. Proc Natl Acad Sci USA 94(22):12041-12046. (Pubitemid 27467839)
32. Dinarello CA. 2002. The IL-1 family and inflammatory diseases. Clin Exp Rheumatol 20(5 Suppl 27):S1-13.
33. Dinarello CA. 2011. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117(14):3720-3732.
34. Dinarello CA, Kim SH. 2006. IL-32, a novel cytokine with a possible role in disease. Ann Rheum Dis 65 Suppl 3:iii61-64. (Pubitemid 44629106)
35. Doodes PD, Cao Y, Hamel KM, Wang Y, Farkas B, Iwakura Y, Finnegan A. 2008. Development of proteoglycan-induced arthritis is independent of IL-17. J Immunol 181(1):329-337.
36. Doodes PD, Cao Y, Hamel KM, Wang Y, Rodeghero RL, Mikecz K, et al. 2010. IFN-gamma regulates the requirement for IL-17 in proteoglycan-induced arthritis. J Immunol 184(3): 1552-1559.
37. Dubois S, Mariner J, Waldmann TA, Tagaya Y. 2002. IL-15Ral-pha recycles and presents IL-15 In trans to neighboring cells. Immunity 17(5):537-547. (Pubitemid 35351500)
38. Edwards SW, Hallett MB. 1997. Seeing the wood for the trees: the forgotten role of neutrophils in rheumatoid arthritis. Immunol Today 18(7):320-324. (Pubitemid 27314467)
39. Ettinger R, Kuchen S, Lipsky PE. 2008. The role of IL-21 in regulating B-cell function in health and disease. Immunol Rev 223:60-86. (Pubitemid 351986176)
40. Fearon U. 2011. Interleukin-27: A master regulator in inflammation. Arthritis Rheum 63(8):2157-2160.
41. Feldmann M, Maini RN. 2010. Anti-TNF therapy, from rationale to standard of care: what lessons has it taught us? J Immunol 185(2):791-794.
42. Ferrari-Lacraz S, Zanelli E, Neuberg M, Donskoy E, Kim YS, Zheng XX, et al. 2004. Targeting IL-15 receptor-bearing cells with an antagonist mutant IL-15/Fc protein prevents disease development and progression in murine collagen-induced arthritis. J Immunol 173(9):5818-5826. (Pubitemid 39392172)
43. Furukawa M, Takaishi H, Takito J, Yoda M, Sakai S, Hikata T, et al. 2009. IL-27 abrogates receptor activator of NF-kappa B ligand-mediated osteoclastogenesis of human granulocyte-macrophage colony-forming unit cells through STAT1-de-pendent inhibition of c-Fos. J Immunol 183(4):2397-2406.
44. Gachter T, Werenskiold AK, Klemenz R. 1996. Transcription of the interleukin-1 receptor-related T1 gene is initiated at different promoters in mast cells and fibroblasts. J Biol Chem 271(1):124-129. (Pubitemid 26026567)
45. Genovese MC, Van den Bosch F, Roberson SA, Bojin S, Biagini IM, Ryan P, Sloan-Lancaster J. 2010. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 62(4):929-939.
46. Giri JG, Ahdieh M, Eisenman J, Shanebeck K, Grabstein K, Ku-maki S, et al. 1994. Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. Embo J 13(12):2822-2830. (Pubitemid 24191692)
47. Goldberg R, Wildbaum G, Zohar Y, Maor G, Karin N. 2004. Suppression of ongoing adjuvant-induced arthritis by neutralizing the function of the p28 subunit of IL-27. J Immunol 173(2):1171-1178. (Pubitemid 38924293)
48. Gonzalez-Alvaro I, Ortiz AM, Garcia-Vicuna R, Balsa A, Pasc-ual-Salcedo D, Laffon A. 2003. Increased serum levels of in-terleukin-15 in rheumatoid arthritis with long-term disease. Clin Exp Rheumatol 21(5):639-642. (Pubitemid 37236459)
49. Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, et al. 2009. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 373(9664):633-640.
50. Gracie JA, Forsey RJ, Chan WL, Gilmour A, Leung BP, Greer MR, et al. 1999. A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest 104(10):1393-1401.
51. Guedez YB, Whittington KB, Clayton JL, Joosten LA, van de Loo FA, van den Berg WB, Rosloniec EF. 2001. Genetic ablation of interferon-gamma up-regulates interleukin-1beta expression and enables the elicitation of collagen-induced arthritis in a nonsusceptible mouse strain. Arthritis Rheum 44(10):2413-2424. (Pubitemid 32977511)
52. Habib T, Senadheera S, Weinberg K, Kaushansky K. 2002. The common gamma chain (gamma c) is a required signaling component of the IL-21 receptor and supports IL-21-induced cell proliferation via JAK3. Biochemistry 41(27):8725-8731. (Pubitemid 34743313)
53. Halvorsen EH, Stronen E, Hammer HB, Goll GL, Sollid LM, Molberg O. 2011. Interleukin-15 induces interleukin-17 production by synovial T cell lines from patients with rheumatoid arthritis. Scand J Immunol 73(3):243-249.
54. Harada S, Yamamura M, Okamoto H, Morita Y, Kawashima M, Aita T, Makino H. 1999. Production of interleukin-7 and in-terleukin-15 by fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Rheum 42(7):1508-1516. (Pubitemid 30265610)
55. Harris ED Jr. 1990. Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med 322(18):1277-1289. (Pubitemid 20152491)
56. Heinhuis B, Koenders MI, van Riel PL, van de Loo FA, Dinarello CA, Netea MG, et al. 2011. Tumour necrosis factor alpha-driven IL-32 expression in rheumatoid arthritis synovial tissue amplifies an inflammatory cascade. Ann Rheum Dis 70(4):660-667.
57. Henningsson L, Jirholt P, Lindholm C, Eneljung T, Silverpil E, Iwakura Y, et al. 2010. Interleukin-17A during local and systemic Staphylococcus aureus-induced arthritis in mice. Infect Immun 78(9):3783-3790.
58. Heo YJ, Joo YB, Oh HJ, Park MK, Heo YM, Cho ML, et al. 2010. IL-10 suppresses Th17 cells and promotes regulatory T cells in the CD4 + T cell population of rheumatoid arthritis patients. Immunol Lett 127(2):150-156.
59. Hirota K, Yoshitomi H, Hashimoto M, Maeda S, Teradaira S, Sugimoto N, et al. 2007. Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J Exp Med 204(12): 2803-2812. (Pubitemid 350179551)
60. Honorati MC, Neri S, Cattini L, Facchini A. 2006. Interleukin-17, a regulator of angiogenic factor release by synovial fibroblasts. Osteoarthritis Cartilage 14(4):345-352.
61. Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, et al. 2010. Effects of AIN457, a fully human antibody to in-terleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2(52):52ra72.
62. Irmler IM, Gajda M, Brauer R. 2007. Exacerbation of antigen-induced arthritis in IFN-gamma-deficient mice as a result of unrestricted IL-17 response. J Immunol 179(9):6228-6236.
63. Jacobs JP, Wu HJ, Benoist C, Mathis D. 2009. IL-17-producing T cells can augment autoantibody-induced arthritis. Proc Natl Acad Sci USA 106(51):21789-21794.
64. Johnston JA, Bacon CM, Finbloom DS, Rees RC, Kaplan D, Shibuya K, et al. 1995. Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15. Proc Natl Acad Sci USA 92(19):8705-8709.
65. Joosten LA, Netea MG, Kim SH, Yoon DY, Oppers-Walgreen B, Radstake TR, et al. 2006. IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci USA 103(9):3298-3303. (Pubitemid 43346464)
66. Ju JH, Cho ML, Moon YM, Oh HJ, Park JS, Jhun JY, et al. 2008. IL-23 induces receptor activator of NF-kappaB ligand expression on CD4+ T cells and promotes osteoclastogenesis in an autoimmune arthritis model. J Immunol 181(2):1507-1518.
67. Jungel A, Distler JH, Kurowska-Stolarska M, Seemayer CA, Seibl R, Forster A, et al. 2004. Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis. Arthritis Rheum 50(5):1468-1476. (Pubitemid 38608068)
68. Kageyama Y, Kobayashi H, Kato N. 2009. Infliximab treatment reduces the serum levels of interleukin-23 in patients with rheumatoid arthritis. Mod Rheumatol 19(6):657-662.
69. Kamiya S, Okumura M, Chiba Y, Fukawa T, Nakamura C, Ni-mura N, et al. 2011. IL-27 suppresses RANKL expression in CD4 (+) T cells in part through STAT3. Immunol Lett. 138:47-53.
70. Kato Z, Jee J, Shikano H, Mishima M, Ohki I, Ohnishi H, et al. 2003. The structure and binding mode of interleukin-18. Nat Struct Biol 10(11):966-971. (Pubitemid 37386108)
71. Katz Y, Nadiv O, Rapoport MJ, Loos M. 2000. IL-17 regulates gene expression and protein synthesis of the complement system, C3 and factor B, in skin fibroblasts. Clin Exp Immunol 120(1):22-29. (Pubitemid 30176895)
72. Kawashiri SY, Kawakami A, Iwamoto N, Fujikawa K, Aramaki T, Tamai M, et al. 2009. Proinflammatory cytokines syner-gistically enhance the production of chemokine ligand 20 (CCL20) from rheumatoid fibroblast-like synovial cells in vitro and serum CCL20 is reduced in vivo by biologic disease-modifying antirheumatic drugs. J Rheumatol 36(11): 2397-2402.
73. Kehlen A, Pachnio A, Thiele K, Langner J. 2003. Gene expression induced by interleukin-17 in fibroblast-like synoviocytes of patients with rheumatoid arthritis: upregulation of hyaluronan-binding protein TSG-6. Arthritis Res Ther 5(4):R186-R192.
74. Kim EY, Chi HH, Bouziane M, Gaur A, Moudgil KD. 2008a. Regulation of autoimmune arthritis by the pro-inflammatory cytokine interferon-gamma. Clin Immunol 127(1):98-106.
75. Kim EY, Moudgil KD. 2009. The determinants of susceptibility/resistance to adjuvant arthritis in rats. Arthritis Res Ther 11(4):239.
76. Kim HR, Cho ML, Kim KW, Juhn JY, Hwang SY, Yoon CH, et al. 2007a. Up-regulation of IL-23p19 expression in rheumatoid arthritis synovial fibroblasts by IL-17 through PI3-kinase-, NF-kappaB-and p38 MAPK-dependent signalling pathways. Rheumatology (Oxford) 46(1):57-64.
77. Kim HR, Kim EY, Cerny J, Moudgil KD. 2006. Antibody responses to mycobacterial and self heat shock protein 65 in autoimmune arthritis: epitope specificity and implication in pathogenesis. J Immunol 177(10):6634-6641. (Pubitemid 44715026)
78. Kim HR, Kim HS, Park MK, Cho ML, Lee SH, Kim HY. 2007b. The clinical role of IL-23p19 in patients with rheumatoid arthritis. Scand J Rheumatol 36(4):259-264.
79. Kim HR, Rajaiah R, Wu QL, Satpute SR, Tan MT, Simon JE, et al. 2008b. Green tea protects rats against autoimmune arthritis by modulating disease-related immune events. J Nutr 138(11): 2111-2116.
80. Kim KW, Cho ML, Kim HR, Ju JH, Park MK, Oh HJ, et al. 2007c. Up-regulation of stromal cell-derived factor 1 (CXCL12) production in rheumatoid synovial fibroblasts through interactions with T lymphocytes: role of interleukin-17 and CD40L-CD40 interaction. Arthritis Rheum 56(4):1076-1086.
81. Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. 2005. In-terleukin-32: a cytokine and inducer of TNFalpha. Immunity 22(1):131-142.
82. Kochetkova I, Golden S, Holderness K, Callis G, Pascual DW. 2010. IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. J Immunol 184(12):7144-7153.
83. Koenders MI, Lubberts E, Oppers-Walgreen B, van den Bersse-laar L, Helsen MM, Di Padova FE, et al. 2005. Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am J Pathol 167(1):141-149. (Pubitemid 40884777)
84. Korn T, Bettelli E, Gao W, Awasthi A, Jager A, Strom TB, et al. 2007. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 448(7152):484-487. (Pubitemid 47123515)
85. Kotake S, Udagawa N, Hakoda M, Mogi M, Yano K, Tsuda E, et al. 2001. Activated human T cells directly induce osteo-clastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 44(5):1003-1012. (Pubitemid 32433604)
86. Kunz M, Ibrahim SM. 2009. Cytokines and cytokine profiles in human autoimmune diseases and animal models of autoim-munity. Mediators Inflamm 2009:979258.
87. Lainer-Carr D, Brahn E. 2007. Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis. Nat Clin Pract Rheumatol 3(8):434-442. (Pubitemid 47193549)
88. Lemos HP, Grespan R, Vieira SM, Cunha TM, Verri WA Jr., Fernandes KS, et al. 2009. Prostaglandin mediates IL-23/IL-17-induced neutrophil migration in inflammation by inhibiting IL-12 and IFNgamma production. Proc Natl Acad Sci USA 106(14):5954-5959.
89. Leonard WJ, Spolski R. 2005. Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation. Nat Rev Immunol 5(9):688-698. (Pubitemid 43086171)
90. Leung BP, Xu D, Culshaw S, McInnes IB, Liew FY. 2004. A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. J Immunol 173(1):145-50. (Pubitemid 38797335)
91. Lipsky PE. 2005. Rheumatoid arthritis. In Kasper D, Braunwald E, Fauci A, Hauser S, Longo D, Jameson J, eds. Harrison's Principles of Internal Medicine. 16th ed. New York: McGraw-Hill. pp 1968-1977.
92. Matsuyama Y, Okazaki H, Hoshino M, Onishi S, Kamata Y, Nagatani K, et al. 2011. Sustained elevation of interleukin-33 in sera and synovial fluids from patients with rheumatoid arthritis non-responsive to anti-tumor necrosis factor: possible association with persistent IL-1beta signaling and a poor clinical response. Rheumatol Int. 2011 Mar 24. Epub ahead of print
93. McInnes IB, Gracie JA. 2004. Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. Curr Opin Pharmacol 4(4):392-397. (Pubitemid 38987067)
94. McInnes IB, Schett G. 2007. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 7(6):429-442. (Pubitemid 46834849)
95. Meyer DM, Jesson MI, Li X, Elrick MM, Funckes-Shippy CL, Warner JD, et al. 2010. Anti-inflammatory activity and neutro-phil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond) 7:41.
96. Miller AM, Xu D, Asquith DL, Denby L, Li Y, Sattar N, et al. 2008. IL-33 reduces the development of atherosclerosis. J Exp Med 205(2):339-346. (Pubitemid 351281600)
97. Moran EM, Mullan R, McCormick J, Connolly M, Sullivan O, Fitzgerald O, et al. 2009. Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies. Arthritis Res Ther 11(4):R113.
98. Moudgil KD, Chang TT, Eradat H, Chen AM, Gupta RS, Brahn E, Sercarz EE. 1997. Diversification of T cell responses to carboxy-terminal determinants within the 65-kD heat-shock protein is involved in regulation of autoimmune arthritis. J Exp Med 185(7):1307-1316. (Pubitemid 27172911)
99. Moudgil KD, Kim E, Yun OJ, Chi HH, Brahn E, Sercarz EE. 2001. Environmental modulation of autoimmune arthritis involves the spontaneous microbial induction of T cell responses to regulatory determinants within heat shock protein 65. J Immunol 166(6):4237-4243. (Pubitemid 32224959)
100. Moussion C, Ortega N, Girard JP. 2008. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? PLoS One 3(10):e3331.
101. Murphy CA, Langrish CL, Chen Y, Blumenschein W, McCla-nahan T, Kastelein RA, et al. 2003. Divergent pro-and anti-inflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 198(12):1951-1957. (Pubitemid 38032126)
102. Niedbala W, Cai B, Wei X, Patakas A, Leung BP, McInnes IB, Liew FY. 2008. Interleukin 27 attenuates collagen-induced arthritis. Ann Rheum Dis 67(10):1474-1479.
103. Niedbala W, Wei XQ, Cai B, Hueber AJ, Leung BP, McInnes IB, Liew FY. 2007. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol 37(11):3021-3209.
104. Niu X, He D, Zhang X, Yue T, Li N, Zhang JZ, et al. 2010. IL-21 regulates Th17 cells in rheumatoid arthritis. Hum Immunol 71(4):334-341.
105. Novick D, Rubinstein M, Azam T, Rabinkov A, Dinarello CA, Kim SH. 2006. Proteinase 3 is an IL-32 binding protein. Proc Natl Acad Sci USA 103(9):3316-3321. (Pubitemid 43346467)
106. Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD, Ma L, et al. 2007. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 448(7152):480-483. (Pubitemid 47123514)
107. Nurmohamed MT. 2009. Newer biological agents in the treatment of rheumatoid arthritis: do the benefits outweigh the risks? Drugs 69(15):2035-2043.
108. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, et al. 2000. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13(5):715-725.
109. Owaki T, Asakawa M, Morishima N, Hata K, Fukai F, Matsui M, et al. 2005. A role for IL-27 in early regulation of Th1 differentiation. J Immunol 175(4):2191-2200. (Pubitemid 41113825)
110. Palmer G, Gabay C. 2011. Interleukin-33 biology with potential insights into human diseases. Nat Rev Rheumatol 7(6):321-329.
111. Palmer G, Talabot-Ayer D, Lamacchia C, Toy D, Seemayer CA, Viatte S, et al. 2009. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum 60(3):738-749.
112. Paradowska-Gorycka A, Grzybowska-Kowalczyk A, Wojtecka-Lukasik E, Maslinski S. 2010. IL-23 in the pathogenesis of rheumatoid arthritis. Scand J Immunol 71(3):134-145.
113. Parham C, Chirica M, Timans J, Vaisberg E, Travis M, Cheung J, et al. 2002. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor sub-unit, IL-23R. J Immunol 168(11):5699-5708. (Pubitemid 34556153)
114. Parrish-Novak J, Foster DC, Holly RD, Clegg CH. 2002. Inter-leukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J Leukoc Biol 72(5):856-863. (Pubitemid 35365159)
115. Parsonage G, Filer A, Bik M, Hardie D, Lax S, Howlett K, et al. 2008. Prolonged, granulocyte-macrophage colony-stimulating factor-dependent, neutrophil survival following rheumatoid synovial fibroblast activation by IL-17 and TNFalpha. Arthritis Res Ther 10(2):R47.
116. Pearson CM. 1956. Development of arthritis, periarthritis and periostitis in rats given adjuvants. Proc Soc Exp Biol Med 91(1):95-101.
117. Pflanz S, Hibbert L, Mattson J, Rosales R, Vaisberg E, Bazan JF, et al. 2004. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol 172(4):2225-2231. (Pubitemid 38182370)
118. Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, Gilbert J, et al. 2002. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4 (+) T cells. Immunity 16(6):779-790. (Pubitemid 34786477)
119. Pickens SR, Chamberlain ND, Volin MV, Mandelin AM 2nd, Agrawal H, Matsui M, et al. 2011. Local expression of inter-leukin-27 ameliorates collagen-induced arthritis. Arthritis Rheum 63(8):2289-2298.
120. Pickens SR, Volin MV, Mandelin AM 2nd, Kolls JK, Pope RM, Shahrara S. 2010. IL-17 contributes to angiogenesis in rheumatoid arthritis. J Immunol 184(6):3233-3241.
121. Plater-Zyberk C, Joosten LA, Helsen MM, Sattonnet-Roche P, Siegfried C, Alouani S, et al. 2001. Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J Clin Invest 108(12):1825-1832. (Pubitemid 34015128)
122. Plum SM, Park EJ, Strawn SJ, Moore EG, Sidor CF, Fogler WE. 2009. Disease modifying and antiangiogenic activity of 2-methoxyestradiol in a murine model of rheumatoid arthritis. BMC Musculoskelet Disord 10:46.
123. Rajaiah R, Puttabyatappa M, Polumuri SK, Moudgil KD. 2011. Interleukin-27 and interferon-gamma are involved in regulation of autoimmune arthritis. J Biol Chem 286(4):2817-2825.
124. Ridge SC, Oronsky AL, Kerwar SS. 1988. Type II collagen-induced arthritis in rats. Methods Enzymol 162:355-360. (Pubitemid 19019522)
125. Robinson D, Shibuya K, Mui A, Zonin F, Murphy E, Sana T, et al. 1997. IGIF does not drive Th1 development but sy-nergizes with IL-12 for interferon-gamma production and activates IRAK and NFkappaB. Immunity 7(4):571-581. (Pubitemid 27508708)
126. Romagnani S. 1997. The Th1/Th2 paradigm. Immunol Today 18(6):263-266. (Pubitemid 27261442)
127. Rong Z, Wang A, Li Z, Ren Y, Cheng L, Li Y, et al. 2009. IL-17RD (Sef or IL-17RLM) interacts with IL-17 receptor and mediates IL-17 signaling. Cell Res 19(2):208-215.
128. Rossler U, Thomassen E, Hultner L, Baier S, Danescu J, Wer-enskiold AK. 1995. Secreted and membrane-bound isoforms of T1, an orphan receptor related to IL-1-binding proteins, are differently expressed in vivo. Dev Biol 168(1):86-97.
129. Ruchatz H, Leung BP, Wei XQ, McInnes IB, Liew FY. 1998. Soluble IL-15 receptor alpha-chain administration prevents murine collagen-induced arthritis: a role for IL-15 in development of antigen-induced immunopathology. J Immunol 160(11):5654-5660. (Pubitemid 28267861)
130. Ruddy MJ, Shen F, Smith JB, Sharma A, Gaffen SL. 2004. In-terleukin-17 regulates expression of the CXC chemokine LIX/CXCL5 in osteoblasts: implications for inflammation and neutrophil recruitment. J Leukoc Biol 76(1):135-144. (Pubitemid 38857180)
131. Ruth JH, Park CC, Amin MA, Lesch C, Marotte H, Shahrara S, Koch AE. 2010. Interleukin-18 as an in vivo mediator of monocyte recruitment in rodent models of rheumatoid arthritis. Arthritis Res Ther 12(3):R118.
132. Ryu S, Lee JH, Kim SI. 2006. IL-17 increased the production of vascular endothelial growth factor in rheumatoid arthritis synoviocytes. Clin Rheumatol 25(1):16-20.
133. Saidi S, Bouri F, Lencel P, Duplomb L, Baud'huin M, Delplace S, et al. 2011. IL-33 is expressed in human osteoblasts, but has no direct effect on bone remodeling. Cytokine 53(3):347-354.
134. Sarkar S, Cooney LA, White P, Dunlop DB, Endres J, Jorns JM, et al. 2009. Regulation of pathogenic IL-17 responses in collagen-induced arthritis: roles of endogenous interferon-gam-ma and IL-4. Arthritis Res Ther 11(5):R158.
135. Satpute SR, Rajaiah R, Polumuri SK, Moudgil KD. 2009. Toleri-zation with Hsp65 induces protection against adjuvant-induced arthritis by modulating the antigen-directed interferon-gamma, interleukin-17, and antibody responses. Arthritis Rheum 60(1):103-113.
136. Sawa S, Lochner M, Satoh-Takayama N, Dulauroy S, Berard M, Kleinschek M, et al. 2011. RORgammat(+) innate lymphoid cells regulate intestinal homeostasis by integrating negative signals from the symbiotic microbiota. Nat Immunol 12(4): 320-326.
137. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. 2005. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23(5):479-490. (Pubitemid 41587888)
138. Scott DL, Smith C, Kingsley G. 2003. Joint damage and disability in rheumatoid arthritis: an updated systematic review. Clin Exp Rheumatol 21(5 Suppl 31):S20-S27. (Pubitemid 37265584)
139. Shahrara S, Huang Q, Mandelin AM, 2nd, Pope RM. 2008. TH-17 cells in rheumatoid arthritis. Arthritis Res Ther 10(4):R93.
140. Shahrara S, Pickens SR, Dorfleutner A, Pope RM. 2009. IL-17 induces monocyte migration in rheumatoid arthritis. J Immunol 182(6):3884-3891.
141. Shen H, Xia L, Lu J, Xiao W. 2010. Infliximab reduces the frequency of interleukin 17-producing cells and the amounts of interleukin 17 in patients with rheumatoid arthritis. J Investig Med 58(7):905-908.
142. Shoda H, Fujio K, Yamaguchi Y, Okamoto A, Sawada T, Kochi Y, Yamamoto K. 2006. Interactions between IL-32 and tumor necrosis factor alpha contribute to the exacerbation of immune-inflammatory diseases. Arthritis Res Ther 8(6):R166.
143. Smeets RL, van de Loo FA, Arntz OJ, Bennink MB, Joosten LA, van den Berg WB. 2003. Adenoviral delivery of IL-18 binding protein C ameliorates collagen-induced arthritis in mice. Gene Ther 10(12):1004-1011. (Pubitemid 36722490)
144. Smolen JS, Maini RN. 2006. Interleukin-6: a new therapeutic target. Arthritis Res Ther 8 Suppl 2:S5.
145. Stolina M, Bolon B, Middleton S, Dwyer D, Brown H, Duryea D, et al. 2009a. The evolving systemic and local biomarker milieu at different stages of disease progression in rat adjuvant-induced arthritis. J Clin Immunol 29(2):158-174.
146. Stolina M, Schett G, Dwyer D, Vonderfecht S, Middleton S, Duryea D, et al. 2009b. RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models:
147. Stumhofer JS, Silver JS, Laurence A, Porrett PM, Harris TH, Turka LA, et al. 2007. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat Immunol 8(12):1363-1371. (Pubitemid 350131173)
148. Szekanecz Z, Koch AE. 2009. Angiogenesis and its targeting in rheumatoid arthritis. Vascul Pharmacol 51(1):1-7.
149. Taurog JD, Argentieri DC, McReynolds RA. 1988. Adjuvant arthritis. Methods Enzymol 162:339-355. (Pubitemid 19019521)
150. Toy D, Kugler D, Wolfson M, Vanden Bos T, Gurgel J, Derry J, et al. 2006. Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J Immunol 177(1):36-39. (Pubitemid 43939112)
151. Trentham DE. 1982. Collagen arthritis as a relevant model for rheumatoid arthritis. Arthritis Rheum 25(8):911-916. (Pubitemid 12047017)
152. Tsuboi N, Ernandez T, Li X, Nishi H, Cullere X, Mekala D, et al. 2010. Human neutrophil FcgammaRIIA regulation by C5aR promotes inflammatory arthritis in mice. Arthritis Rheum. 2010 Nov 12. Epub ahead of print
153. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. 2006. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24(2):179-189. (Pubitemid 43214587)
154. Venkatesha SH, Yu H, Rajaiah R, Tong L, Moudgil KD. 2011. Celastrus-derived Celastrol suppresses autoimmune arthritis by modulating antigen-induced cellular and humoral effector responses. J Biol Chem. 286(17):15138-15146.
155. Vermeire K, Heremans H, Vandeputte M, Huang S, Billiau A, Matthys P. 1997. Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. J Immunol 158(11):5507-5513. (Pubitemid 127681260)
156. Villarino AV, Hunter CA. 2004. Biology of recently discovered cytokines: discerning the pro-and anti-inflammatory properties of interleukin-27. Arthritis Res Ther 6(5):225-233. (Pubitemid 40124374)
157. Volin MV, Koch AE. 2011. Interleukin-18: a mediator of inflammation and angiogenesis in rheumatoid arthritis. J Inter-feron Cytokine Res 31(10):745-751.
158. Wang D, Chang Y, Wu Y, Zhang L, Yan S, Xie G, et al. 2011. Therapeutic effects of TACI-Ig on rat with adjuvant arthritis. Clin Exp Immunol 163(2):225-234.
159. Wei XQ, Leung BP, Arthur HM, McInnes IB, Liew FY. 2001. Reduced incidence and severity of collagen-induced arthritis in mice lacking IL-18. J Immunol 166(1):517-521. (Pubitemid 32038471)
160. Wiekowski MT, Leach MW, Evans EW, Sullivan L, Chen SC, Vassileva G, et al. 2001. Ubiquitous transgenic expression of the IL-23 subunit p19 induces multiorgan inflammation, runting, infertility, and premature death. J Immunol 166(12):7563-7570. (Pubitemid 32525637)
161. Wong CK, Chen da P, Tam LS, Li EK, Yin YB, Lam CW. 2010. Effects of inflammatory cytokine IL-27 on the activation of fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Res Ther 12(4):R129.
162. Wooley PH. 1988. Collagen-induced arthritis in the mouse. Methods Enzymol 162:361-373. (Pubitemid 19019523)
163. Wurster AL, Rodgers VL, Satoskar AR, Whitters MJ, Young DA, Collins M, Grusby MJ. 2002. Interleukin 21 is a T helper (Th) cell 2 cytokine that specifically inhibits the differentiation of naive Th cells into interferon gamma-producing Th1 cells. J Exp Med 196(7):969-977.
164. Xu D, Jiang HR, Kewin P, Li Y, Mu R, Fraser AR, et al. 2008. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci USA 105(31):10913-10918.
165. Xu D, Jiang HR, Li Y, Pushparaj PN, Kurowska-Stolarska M, Leung BP, et al. 2010. IL-33 exacerbates autoantibody-induced arthritis. J Immunol 184(5):2620-2626.
166. Yago T, Nanke Y, Kawamoto M, Furuya T, Kobashigawa T, Kamatani N, Kotake S. 2007. IL-23 induces human osteoclas-togenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res Ther 9(5):R96.
167. Yamamoto Y, Kato Z, Matsukuma E, Li A, Omoya K, Hashimoto K, et al. 2004. Generation of highly stable IL-18 based on a ligand-receptor complex structure. Biochem Biophys Res Commun 317(1):181-186. (Pubitemid 38401981)
168. Yamamura M, Kawashima M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M, et al. 2001. Interferon-gamma-inducing activity of interleukin-18 in the joint with rheumatoid arthritis. Arthritis Rheum 44(2):275-285. (Pubitemid 32207020)
169. Yang J, Yang M, Htut TM, Ouyang X, Hanidu A, Li X, et al. 2008a. Epstein-Barr virus-induced gene 3 negatively regulates IL-17, IL-22 and RORgamma t. Eur J Immunol 38(5):1204-1214.
170. Yang L, Anderson DE, Baecher-Allan C, Hastings WD, Bettelli E, Oukka M, et al. 2008b. IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature 454(7202): 350-352.
171. Yang YH, Rajaiah R, Lee DY, Ma Z, Yu H, Fong HH, et al. 2011. Suppression of ongoing experimental arthritis by a chinese herbal formula (huo-luo-xiao-ling dan) involves changes in antigen-induced immunological and biochemical mediators of inflammation. Evid Based Complement Alternat Med 2011: 642027.
172. Yoshihara K, Yamada H, Hori A, Yajima T, Kubo C, Yoshikai Y. 2007. IL-15 exacerbates collagen-induced arthritis with an enhanced CD4+ T cell response to produce IL-17. Eur J Immunol 37(10):2744-2752. (Pubitemid 47578293)
173. Young DA, Hegen M, Ma HL, Whitters MJ, Albert LM, Lowe L, et al. 2007. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum 56(4):1152-1163. (Pubitemid 46608640)
174. Yu H, Yang YH, Rajaiah R, Moudgil KD. 2011. Nicotine-induced differential modulation of autoimmune arthritis in the Lewis rat involves changes in interleukin-17 and anti-cyclic citrullinated peptide antibodies. Arthritis Rheum 63(4):981-991.
175. Ziolkowska M, Koc A, Luszczykiewicz G, Ksiezopolska-Pietrzak K, Klimczak E, Chwalinska-Sadowska H, Maslinski W. 2000. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol 164(5):2832-2838. (Pubitemid 30115519)